Grants for Nonprofits - Science and Technology

The Community Foundation for Northeast Florida is offering Small Arts Organization Grants to support small and mid-size arts and cultural organizations in the Northeast Florida region. This funding aims to enhance organizational capacity-building and program development within the arts and culture sector. The foundation's mission, as evidenced by this grant, aligns with fostering a vibrant cultural landscape in the region by investing in the growth and stability of local arts organizations. The target beneficiaries of this grant are small to mid-sized arts and cultural organizations with current 501(c)(3) status or a formal fiscal sponsorship agreement, along with a minimum two-year work history. These organizations must be primarily focused on arts and culture and be based in Baker, Clay, Duval, Nassau, Putnam, or St. Johns County, Florida. The impact goals are to strengthen these organizations, enabling them to expand their reach, improve their programs, and contribute more effectively to the cultural enrichment of their communities. The grant prioritizes initiatives that focus on organizational development and program enhancement, providing funding between $1,000 and $10,000. This focus suggests a strategic approach by the Community Foundation to not only fund individual projects but also to build the long-term sustainability and effectiveness of arts organizations. By strengthening the foundational capacity of these groups, the foundation aims to create a more robust and resilient arts ecosystem in Northeast Florida. Expected outcomes include improved operational efficiency, expanded programming, and increased community engagement by recipient organizations. While specific measurable results are not detailed in the provided text, the emphasis on capacity-building and program development implies a focus on quantifiable improvements in these areas, such as increased audience participation, diversified funding streams, or the development of new and impactful artistic programs. This strategic funding approach reflects the Community Foundation for Northeast Florida's theory of change, which posits that investing in the foundational strength of arts and cultural organizations leads to greater community benefit and a richer cultural environment.

The Entergy Charitable Foundation, in partnership with the NFL Foundation and other key organizations, is spearheading the Super Bowl LIX Legacy Program, "Impact 59 Powered by Entergy." This initiative aims to leave a lasting legacy of philanthropy and economic impact within the Greater New Orleans community, aligning with Entergy's broader mission of community support and development. The program's strategic approach focuses on fostering positive change through collaborative efforts with local nonprofit partners, reflecting a commitment to leveraging significant events like the Super Bowl for long-term community benefit. The primary target beneficiaries of the "Impact 59" grants are underserved populations within ten specific parishes in Louisiana: Orleans, Jefferson, St. Bernard, St. Charles, St. James, St. John the Baptist, Plaquemines, St. Tammany, Tangipahoa, and Washington. The program aims to achieve significant impact in several key areas, including Youth Development, Workforce Training, Education, Health & Wellness, and Equity & Inclusion. The overarching goal is to enhance the quality of life, increase opportunities, and promote a more equitable environment for marginalized individuals and groups within these communities. The program's priorities and focuses are clearly defined. In Youth Development, the emphasis is on mentoring, physical and mental well-being, and engaging youth through sports, health clinics, and specialized training. Workforce Training focuses on increasing employability for underserved populations, including the formerly incarcerated, to secure living wage jobs. Education seeks to improve access to quality education through contemporary learning programs. Health & Wellness aims to enhance access to services for underserved communities, supporting health, nutrition, and food programs. Finally, Equity & Inclusion is dedicated to improving experiences for marginalized individuals and guaranteeing fair treatment, access, opportunity, and advancement for all. Expected outcomes include a minimum of $3 million in grants distributed to local nonprofit partners. Grants will range from $25,000 to $250,000, with smaller organizations (under $500,000 annual budget) eligible for $25,000 to $50,000, and larger organizations receiving up to $250,000. Measurable results will stem from the impact of funded programs in addressing the identified focus areas, contributing to a legacy of improved community well-being and economic empowerment. The foundation's theory of change posits that by strategically investing in these critical areas through local nonprofits, they can create a ripple effect of positive societal transformation, ultimately building stronger, more resilient communities in the Greater New Orleans area.

The DC Commission on the Arts and Humanities (CAH) is offering a grant program to support the development and public presentation of visual art exhibitions. This initiative aligns with CAH's mission to foster artistic and cultural development within the District of Columbia by providing opportunities for local artists and curators. The grant aims to enhance the cultural landscape of D.C. through innovative and educational art exhibitions, utilizing CAH's exhibition space and virtual platforms. The primary target beneficiaries of this grant are District resident curators and nonprofit organizations with curatorial capacity. The program seeks to empower these individuals and groups to develop and present compelling visual art exhibitions. The impact goals include providing opportunities for D.C. resident curators to showcase new works or bring existing exhibitions from other cities to the District, thereby enriching the cultural experiences available to local residents. The program prioritizes fostering innovative and educational art exhibitions. Key focus areas include supporting the presentation of visual art in a government facility and offering unique exhibitions and related programs for District residents. Expected outcomes include an increase in the number and diversity of art exhibitions available in D.C., greater visibility for local curators and artists, and enhanced engagement of District residents with the arts. Funding for individuals and new nonprofit organizations in FY25 can be up to $30,000, or $35,000 if working with a co-curator or curatorial mentee, with a grant period from October 1, 2024, to September 30, 2025. Eligibility criteria for individuals include being an artist, curator, or arts-related professional over 18 with prior curatorial experience, maintaining D.C. residency, and being in good standing with CAH. Nonprofit organizations must be 501(c)(3) certified, have a principal business office in D.C., be registered to do business in the District, ensure at least 51% of activities occur in D.C., and obtain Citywide Clean Hands certification. Colleges, universities, service organizations, foreign governments, and other DC/Federal Government agencies are ineligible.

This grant provides funding and technical assistance to organizations that help state, local, and Tribal governments improve their planning and permitting processes for large-scale renewable energy projects.

The North Central Region SARE (NCR-SARE) Research and Education (R&E) Grant Program is a competitive funding opportunity offering $100,000 to $500,000 for up to 3 years to researchers, educators, and organizations exploring sustainable agriculture, with the aim of improving economic viability, environmental quality, and quality of life in the North Central Region's agricultural sector.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity supports nonprofit organizations in Manhattan and Riley County, Kansas, to create accessible and lasting public arts projects that enrich community life.

This program provides coaching and community support for fundraisers of color at small nonprofits in Sacramento and Yolo counties, focusing on those addressing health and racial disparities.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Levels 1 and 2. Funding Levels 3 and 4 are available under other program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcement before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement: Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome. Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within thebreast cancer landscape. Funding Level 2: Population Science and Prevention Studies: Population Science and Prevention Studies should involve investigations into why certain human patient populations differ in cancer risk or clinical prognosis. The studies should focus on the analysis of human data and biospecimens. Research should be already supported by substantial preliminary or published data and strongly validate clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Levels 1 and 2 applications unless they are clearly unique, meaningful partnerships addressing distinct research questions. Applications in which a mentor and their current postdoctoral fellow or junior investigator are named as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most, or all of the experiments and analyses, do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.Applications seeking support for a clinical trial may be submitted to the FY24 BCRP Breakthrough Award Level 3 and Level 4 program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively).A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 1 should not exceed $450,000 for applications with a single PI or $750,000 if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 2 should not exceed $1.0M for applications with a single PI or $1.5M if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 2, Population Science and Prevention Studies, should not exceed $1.5M for applications with a single PI or $2.0M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $20.9M to fund approximately 14 Breakthrough Award Levels 1 and 2 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides additional financial support to active health services research projects facing unforeseen costs, helping researchers continue their work effectively.

The Opelousas Downtown Development District (ODDD), with support from the City of Opelousas and Opelousas Main Street (OMS), is launching the fifth round of funding for its Building Improvement Grant (BIG) program. This program is a grant/reimbursement initiative designed to empower property and business owners in rehabilitating commercial buildings. The overarching mission alignment for this program is to create a positive visual impact within the city, stimulate private investment, and diligently preserve Opelousas' historic identity and cultural assets. The primary beneficiaries of this grant program are property and business owners within the Opelousas Downtown Development District who own commercial buildings. The core impact goals are to foster economic development through private investment, enhance the aesthetic appeal of the downtown area, and ensure the safeguarding of the city's rich historical and cultural heritage. The program directly supports the revitalization of commercial spaces, which, in turn, contributes to a more vibrant and economically robust downtown. The program's priorities and focuses are clearly on tangible and permanent building improvements. Eligible uses of funds are comprehensive, including restoration and renovation of buildings, installation of awnings (without signage), brick cleaning or re-pointing, accent lighting, removal of deteriorating or inappropriate materials visible from the street, and restoration of windows, doors, and original exterior/interior architectural features. Additionally, interior work related to ceiling repair, electrical, and plumbing is covered, as well as work on roofs, cornices, gutters, downspouts, and the cleaning, preparation, and painting of walls and trim. These priorities are aimed at holistic improvement of commercial properties. The expected outcomes include a noticeable improvement in the visual appeal of downtown Opelousas, an increase in private investment in commercial properties, and the successful preservation of historic buildings. While not explicitly stated as "measurable results" in the traditional sense, the program's structure and goals imply that the number of rehabilitated buildings, the amount of private investment stimulated, and the visible improvements in the downtown area would serve as key indicators of success. The program offers a total of $200,000 in grant funds, with a maximum application amount of $10,000 per project, providing a clear framework for financial allocation and impact tracking.

This funding opportunity provides up to $50,000 for organizations to implement urban forestry projects in underserved communities, enhancing green spaces and environmental quality on public lands.

The Emporia Community Foundation in Butler County, Kansas is offering a grant through the Flint Hills Community Fund for community and rural development, museums/historic preservation, and agriculture and conservation projects, prioritizing those with high volunteer involvement and organizations looking to expand, with applications due by 09/30/2024.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

Grant Name: CCEF Rapid Grants Location: Georgia Description: The Cherokee County Educational Foundation (CCEF) is offering rapid grants to support growth and innovation in the Cherokee County School District. These grants, with funding of up to $500, are available to all faculty members for activities such as inviting authors to speak, organizing in-school field trips, and conducting science lab projects. The aim is to provide teachers and students with the necessary tools to make learning exciting. For more details, visit the Rapid Grants webpage.

The Rowan Arts Council (RAC) Grassroots Arts grants are provided annually to non-profit organizations operating arts programs within Rowan County, North Carolina. This program is funded through the NC General Assembly via the NC Arts Council Grassroots Arts Program, with the RAC acting as the Designated County Partner. The primary mission of these grants aligns with enhancing and strengthening the cultural community and broadening artistic services available to Rowan County citizens. The program focuses on fostering a vibrant arts scene and making arts accessible to a wider audience, contributing to the cultural enrichment of the region. The grants target a diverse range of beneficiaries, including qualified arts organizations such as theaters, symphonies, galleries, art guilds, choral societies, dance companies, folk arts societies, writer’s groups, and arts festivals. Additionally, the program supports arts learning and arts in education initiatives for students and adults, as well as community organizations providing quality art experiences. The expected outcomes include a more robust cultural landscape, increased participation in arts programs, and expanded artistic services. Measurable results could include the number of organizations supported, the number of individuals reached through various programs, and the diversity of artistic offerings. The program prioritizes funding in three key areas. The first priority is to offer program or operating support to qualified arts organizations that do not receive funding directly from the N.C. Arts Council’s State Arts Resources. The second priority is to support arts learning and arts in education programs, such as artist residencies in schools, after-school camps, or adult arts classes, provided these activities are not part of a school's internal arts curriculum or for the purchase of art supplies or student competitions. The third priority is to support other community organizations that provide quality art experiences for the greater community, ensuring these programs are conducted by qualified artists. Grassroots Arts Program funds can be utilized across various artistic disciplines, including visual arts, crafts, dance, drama, film and video, folk arts, literature, music, photography, architecture, and the visual environment. Typical uses of funds encompass program expenses like artists’ fees, travel, space rental, advertising, and supplies, as well as program administration and operating expenses such. While salaries and equipment are allowable, their use is generally limited. The program strategically aims to build a strong, self-sustaining arts community in Rowan County by empowering local organizations and artists, which aligns with a theory of change that increased local investment in the arts leads to broader community engagement and cultural development.

This funding opportunity provides financial support for researchers at domestic institutions to study atmospheric processes using data from the Department of Energy's ARM facility, with a focus on improving climate models and understanding critical environmental factors.

This funding opportunity supports researchers and educational institutions in developing engineered microbial communities to advance scientific understanding and practical solutions for climate change, sustainability, and biotechnology.

This funding opportunity supports research and development projects aimed at advancing air dominance technologies, targeting higher education institutions, non-profits, for-profits, and small businesses involved in innovative defense solutions.

Texas Mutual is offering a grant program designed to create generational impact and build a stronger, safer Texas for working families. This initiative aligns directly with their mission to support the well-being of the state's workforce and their dependents. The grant's duration is one year, with funding requests encouraged between $25,000 and $100,000, though the overall size of the grant can range from $10,000 to $100,000. The primary beneficiaries of this funding cycle are Texas workers and their families, with a focus on improving health and wellness, and expanding access to quality early childhood education. The grant also targets clients who require holistic wraparound support in addition to case management to overcome multiple barriers and seize opportunities. The overarching impact goals are to enhance health outcomes, improve educational access for young children, and provide comprehensive support systems for families in need. The program's priorities and focuses for this grant cycle include organizations dedicated to improving the health and wellness of Texas workers and their families by ensuring access to quality care and health education. Another key area is strengthening the early childhood education system, specifically by equipping child care providers with the necessary resources to deliver affordable, quality education. Finally, the grant seeks to support nonprofits that provide or coordinate integrated care, addressing various barriers through holistic wraparound support and case management. Texas Mutual's strategic priorities are centered on long-term societal improvement through targeted investments. Their theory of change appears to be that by investing in health, education, and comprehensive family support, they can create a ripple effect that leads to a stronger, safer, and more prosperous Texas for working families across generations. This involves ensuring that organizations are actively delivering technical assistance and services within Texas communities. Expected outcomes include increased access to quality healthcare and health education for Texas workers, an enhanced early childhood education system with more accessible and affordable options, and improved stability and opportunity for families through integrated support services. While specific measurable results are not detailed, the focus on "generational impact" suggests long-term, sustainable improvements in the well-being and socio-economic conditions of Texas working families as a result of these initiatives.